Vimarsana
Biggest News Aggregation in the World

Page 15 - Randomized Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Trial Today - Breaking & Trending Today

University of Virginia: UVA Health Joins National Trial Testing Medications For Mild To Moderate Covid-19 - Vimarsana News

University of Virginia: UVA Health Joins National Trial Testing Medications For Mild To Moderate Covid-19

UVA Health has joined a nationwide study evaluating two repurposed medications in the search for effective, safe treatments for mild to moderate COVID-19. Repurposed medications are already approved by the U.S. Food and Drug Administration for the tr

Ivermectin for COVID Virginia Hospital Clinical Study - Vimarsana News

Ivermectin for COVID Virginia Hospital Clinical Study

People from throughout Virginia and across the U.S. can get more information on how to participate in COVID ivermectin trial activ6study.org or 833.385.1880.

UVA Health joins trial testing medications for mild-to-moderate COVID-19 - Vimarsana News

UVA Health joins trial testing medications for mild-to-moderate COVID-19

UVA Health has joined a nationwide study evaluating two repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19.

Ivermectin for COVID Virginia Hospital Clinical Study - Vimarsana News

Ivermectin for COVID Virginia Hospital Clinical Study

People from throughout Virginia and across the U.S. can get more information on how to participate in COVID ivermectin trial activ6study.org or 833.385.1880.

Source: wusa9.com
Study to evaluate efficacy of higher dose of ivermectin for treating mild-to-moderate COVID-19 - Vimarsana News

Study to evaluate efficacy of higher dose of ivermectin for treating mild-to-moderate COVID-19

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University has expanded its testing platform to evaluate ivermectin at a higher dose for a longer period of time.